TY - JOUR
T1 - Phase-Change Materials Based Nanoparticles for Controlled Hypoxia Modulation and Enhanced Phototherapy
AU - Zhang, Shichao
AU - Li, Qinzhe
AU - Yang, Nan
AU - Shi, Yunhao
AU - Ge, Wei
AU - Wang, Wenjun
AU - Huang, Wei
AU - Song, Xuejiao
AU - Dong, Xiaochen
N1 - Publisher Copyright:
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Tumor hypoxia strengthens tumor resistance to different therapies especially oxygen involved strategies, such as photodynamic therapy (PDT). Herein, the thermal responsive phase change materials (PCM) are utilized to coencapsulate ultrasmall manganese dioxide (sMnO2) and organic photosensitizer IR780 to obtain IR780-sMnO2-PCM nanoparticles for controlled tumor hypoxia modulation and enhanced phototherapy. The thermal responsive protective PCM layer can not only prevent IR780 from photodegradation, but also immediately release sMnO2 to decompose endogenous H2O2 and generate enough oxygen for PDT under laser irradiation. Owing to the efficient accumulation of IR780-sMnO2-PCM nanoparticles in tumor under intravenous injection as revealed by both florescence imaging and photoacoustic imaging, the tumor hypoxia is greatly relieved. Furthermore, in vivo combined photothermal therapy (PTT) and PDT, IR780-sMnO2-PCM nanoparticles, compared to IR780-PCM nanoparticles, exhibit better performance in inhibiting tumor growth. The results highlight the promise of IR780-sMnO2-PCM in controlled modulation of tumor hypoxia to overcome current limitations of cancer therapies.
AB - Tumor hypoxia strengthens tumor resistance to different therapies especially oxygen involved strategies, such as photodynamic therapy (PDT). Herein, the thermal responsive phase change materials (PCM) are utilized to coencapsulate ultrasmall manganese dioxide (sMnO2) and organic photosensitizer IR780 to obtain IR780-sMnO2-PCM nanoparticles for controlled tumor hypoxia modulation and enhanced phototherapy. The thermal responsive protective PCM layer can not only prevent IR780 from photodegradation, but also immediately release sMnO2 to decompose endogenous H2O2 and generate enough oxygen for PDT under laser irradiation. Owing to the efficient accumulation of IR780-sMnO2-PCM nanoparticles in tumor under intravenous injection as revealed by both florescence imaging and photoacoustic imaging, the tumor hypoxia is greatly relieved. Furthermore, in vivo combined photothermal therapy (PTT) and PDT, IR780-sMnO2-PCM nanoparticles, compared to IR780-PCM nanoparticles, exhibit better performance in inhibiting tumor growth. The results highlight the promise of IR780-sMnO2-PCM in controlled modulation of tumor hypoxia to overcome current limitations of cancer therapies.
KW - cancer theranostics
KW - hypoxia modulation
KW - phase change materials
KW - photodynamic therapy
UR - http://www.scopus.com/inward/record.url?scp=85074459876&partnerID=8YFLogxK
U2 - 10.1002/adfm.201906805
DO - 10.1002/adfm.201906805
M3 - 文章
AN - SCOPUS:85074459876
SN - 1616-301X
VL - 29
JO - Advanced Functional Materials
JF - Advanced Functional Materials
IS - 49
M1 - 1906805
ER -
